Skip to NavigationSkip to content

Fiasp

Novo Nordisk's Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients

New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better option for child and adolescent patients with type 1 diabetes to manage their blood sugar levels compared to existing therapies when administered multiple times a day.

The data, presented at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), demonstrated that patients using Fiasp at mealtimes saw “superior reductions in overall blood sugar levels (HbA1c)”, compared to conventional insulin aspart.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches